Skip to main content

Table 2 FeNO change from baseline ratio following onset and cessation of treatment

From: Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

A: FeNO change from baseline and FF/VI:placebo ratio following onset of treatment

Day of treatment

Time point

Geometric LSmean

Ratio (FF/VI vs Placebo)

95% CI of the Ratio

n

FF/VI 100/25 mcg

n

Placebo

  

1

PM

25

0.97

26

0.90

1.09

(0.91,1.29)

2

AM

27

0.91

27

1.00

0.91

(0.77,1.07)

 

PM

27

0.81

25

0.89

0.91

(0.77,1.08)

3

AM

27

0.75

27

0.95

0.79

(0.67,0.94)

 

PM

27

0.64

25

0.88

0.72

(0.61,0.86)

4

AM

26

0.52

27

0.90

0.58

(0.49,0.69)

 

PM

27

0.48

27

0.89

0.54

(0.46,0.64)

5

AM

27

0.46

27

0.99

0.47

(0.39,0.55)

 

PM

26

0.45

26

0.95

0.47

(0.40,0.56)

6

AM

26

0.45

27

0.97

0.46

(0.39,0.55)

 

PM

27

0.41

27

0.96

0.42

(0.36,0.50)

7

AM

27

0.45

26

0.96

0.47

(0.39,0.56)

 

PM

27

0.39

27

0.88

0.45

(0.38,0.53)

8

AM

27

0.40

27

0.94

0.43

(0.37,0.51)

 

PM

27

0.37

26

0.90

0.41

(0.34,0.48)

9

AM

26

0.39

27

0.99

0.40

(0.33,0.47)

 

PM

25

0.34

25

0.89

0.38

(0.32,0.46)

10

AM

26

0.36

26

0.93

0.39

(0.33,0.46)

 

PM

27

0.36

26

0.90

0.40

(0.34,0.47)

11

AM

27

0.33

27

0.92

0.36

(0.30,0.42)

 

PM

27

0.31

27

0.88

0.36

(0.30,0.42)

12

AM

27

0.39

27

0.94

0.42

(0.35,0.49)

 

PM

27

0.35

27

0.91

0.39

(0.33,0.46)

13

AM

24

0.34

25

0.99

0.35

(0.29,0.41)

 

PM

24

0.32

25

0.94

0.34

(0.29,0.40)

14

AM

23

0.38

23

1.00

0.37

(0.32,0.44)

 

PM

23

0.32

22

1.00

0.32

(0.27,0.37)

B: FeNO change from baseline and FF/VI:placebo ratio following cessation of treatment

Day relative to last dose

Time point

Geometric LSmean

Ratio (FF/VI vs Placebo)

95% CI of the Ratio

  

n

FF/VI 100/25 mcg

n

Placebo

  

1

AM

27

0.38

27

1.03

0.36

(0.31,0.43)

 

PM

27

0.32

27

0.98

0.33

(0.28, 0.39)

2

AM

27

0.38

27

0.99

0.38

(0.32, 0.45)

 

PM

27

0.35

27

0.94

0.37

(0.31, 0.44)

3

AM

27

0.45

27

0.98

0.46

(0.39, 0.54)

 

PM

27

0.42

27

0.91

0.47

(0.40, 0.56)

4

AM

27

0.55

27

0.98

0.56

(0.47, 0.66)

 

PM

27

0.49

27

0.85

0.58

(0.49, 0.69)

5

AM

27

0.52

27

0.83

0.63

(0.53, 0.75)

 

PM

26

0.48

26

0.72

0.67

(0.57, 0.80)

6

AM

26

0.53

26

0.79

0.67

(0.56, 0.80)

 

PM

26

0.48

24

0.78

0.62

(0.52, 0.74)

7

AM

27

0.49

27

0.82

0.60

(0.51, 0.71)

 

PM

25

0.49

25

0.79

0.62

(0.52, 0.74)

8

AM

27

0.56

25

0.82

0.69

(0.58, 0.81)

 

PM

26

0.56

27

0.82

0.68

(0.57, 0.80)

9

AM

27

0.61

27

0.92

0.66

(0.56, 0.78)

 

PM

27

0.62

27

0.91

0.68

(0.57, 0.80)

10

AM

26

0.66

24

1.01

0.66

(0.55, 0.78)

 

PM

27

0.67

27

0.98

0.68

(0.58, 0.81)

11

AM

26

0.77

26

1.06

0.73

(0.61, 0.86)

 

PM

27

0.74

27

1.01

0.73

(0.61, 0.86)

12

AM

27

0.73

27

1.01

0.72

(0.61, 0.85)

 

PM

27

0.70

27

0.99

0.71

(0.60, 0.84)

13

AM

25

0.76

27

1.05

0.72

(0.61, 0.86)

 

PM

25

0.74

25

0.95

0.78

(0.66, 0.93)

14

AM

27

0.79

26

1.00

0.79

(0.66, 0.93)

 

PM

26

0.63

25

0.95

0.67

(0.56, 0.79)

15

AM

26

0.76

26

0.97

0.79

(0.66, 0.93)

 

PM

25

0.73

25

0.92

0.79

(0.66, 0.94)

16

AM

27

0.75

26

1.01

0.74

(0.62, 0.87)

 

PM

27

0.73

26

1.01

0.73

(0.61, 0.86)

17

AM

26

0.79

25

1.03

0.77

(0.65, 0.91)

 

PM

16

0.79

18

0.97

0.81

(0.65, 1.01)

18

AM

14

0.75

17

0.98

0.77

(0.61, 0.96)

 

PM

10

0.67

14

0.87

0.77

(0.59, 1.00)

19

AM

10

0.78

14

0.96

0.81

(0.63, 1.05)

 

PM

6

0.67

12

0.93

0.72

(0.52, 1.00)

20

AM

6

0.77

12

0.99

0.78

(0.56, 1.09)

 

PM

5

0.72

7

0.92

0.78

(0.53, 1.14)

21

AM

6

0.85

7

1.00

0.85

(0.59, 1.22)

 

PM

5

0.75

7

0.99

0.75

(0.50, 1.13)

  1. Legend: Summary of repeated measures statistical analysis of ratio from baseline exhaled nitric oxide (ppb) data after A) onset and B) cessation of repeat dose of treatment. Decrease in n value is seen from Day 17 after last dose due to permitted study visit windows